[MSC] 300/ 300--- 2023-01-11 [mcc] 350/ 350--- 2022-12-07 [RCL] 470/ 550--- 2022-12-05 [RCL] 440/ 600--- 2022-12-01 [Emc] 680/ 930--- 2022-08-11 [Emc] 1925/ 2400--- 2022-05-24 [Rcl] 1770/ 2600--- 2022-05-16 [One] 1525/ 2050--- 2022-05-08 ...
MSC MURATA村田 MURR Molex莫莱克斯 Mutewei NATION/国民技术 NICHICON NIKO-SEM/尼克森 NK/南科功率 NOVOSENSE/纳芯微 OB(昂宝) OCN/亚奇 ON/FSC PADAUK/应广 PPT PTL PUYA/普冉 QORVO/威讯 Quectel移远 RAMTRON RICHTEK(台湾立_) RYCHIP/蕊源 Rubycon/红宝石 SEMIKRON西门康 SINOWEALTH SITRONIX/矽创 SLC SR/芯...
Information on additional cellular therapies was subdivided into: HSC for non-hematopoietic use; non-hematopoietic stem cell therapies; MSC therapies for rejection or GVHD prevention/treatment; and DLI. Collection of information was validated by cross-checking with a similar more detailed survey carried...
Information on additional cellular therapies was subdivided into: HSC for non-hematopoietic use; non-hematopoietic stem cell therapies; MSC therapies for rejection or GvHD prevention/treatment; and donor lymphocyte infusions. Collection of information was harmonized with Bone Marrow Transplantation (2013) ...
Mesenchymal stem cell (MSC) transfusions have been shown to reverse fulminant hepatic failure in mice and to improve liver function in patients with end-stage liver diseases. We assessed the safety and initial efficacy of umbilical cord-derived MSC (UC-MSC) transfusions for ACLF patients ...
MSC MURATA村田 MURR Molex莫莱克斯 Mutewei NATION/国民技术 NICHICON NIKO-SEM/尼克森 NK/南科功率 NOVOSENSE/纳芯微 OB(昂宝) OCN/亚奇 ON/FSC PADAUK/应广 PPT PTL PUYA/普冉 QORVO/威讯 Quectel移远 RAMTRON RICHTEK(台湾立_) RYCHIP/蕊源 Rubycon/红宝石 SEMIKRON西门康 SINOWEALTH SITRONIX/矽创 SLC SR/芯...